Compare HLN & CCEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLN | CCEP |
|---|---|---|
| Founded | 2022 | 1986 |
| Country | United Kingdom | United Kingdom |
| Employees | 24524 | N/A |
| Industry | Package Goods/Cosmetics | Beverages (Production/Distribution) |
| Sector | Consumer Discretionary | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5B | 48.3B |
| IPO Year | N/A | 2015 |
| Metric | HLN | CCEP |
|---|---|---|
| Price | $9.87 | $106.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $104.33 |
| AVG Volume (30 Days) | ★ 11.1M | 2.0M |
| Earning Date | 02-26-2026 | 02-17-2026 |
| Dividend Yield | 1.94% | ★ 2.48% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.55 | $4.86 |
| Revenue Next Year | $4.42 | $3.79 |
| P/E Ratio | $49.05 | ★ $20.93 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.65 | $84.66 |
| 52 Week High | $11.28 | $113.67 |
| Indicator | HLN | CCEP |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 51.56 |
| Support Level | $9.56 | $89.82 |
| Resistance Level | $10.06 | $109.28 |
| Average True Range (ATR) | 0.17 | 2.25 |
| MACD | -0.03 | -0.44 |
| Stochastic Oscillator | 35.51 | 37.45 |
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe, Australasia, and Southeast Asia. In 2025, CCEP sold 3.9 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume.TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.